RxDoctor Payments Data

Octavian Ioachimescu, MD

Pulmonary Disease · Milwaukee, WINPI 1902965726

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,546 of the $2,053 with a category attached, or 75.3%. Every reported general payment came from a single manufacturer, Astrazeneca UK Limited.

$2,053in general payments, 2019–2025

Across 13 payments — averaging $157.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$2K
$333,719in research payments, 2019–2025

Across 34 payments — averaging $9815.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$230K
  • Novartis$38K
  • AstraZeneca$38K
  • Sanofi US Services Inc.$29K
  • Merck$43

What the payments were for

  • Travel & lodging$1,54675%
  • Food & beverage$50725%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited13$2,053

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,053 in reported general payments places this provider in the 65th percentile of 247 pulmonary disease providers in Wisconsin.

See all pulmonary disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$2,031
Medicare patients
13
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →